Propanc Biopharma Inc (PPCB)

[Lhmoobvaj]

Positive news for PPCHD:

The best time to invest in a small-cap biotech company is prior to/during successful clinical trials. Propanc Biopharma, Inc. (PPCHD) is a development stage healthcare company focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with their scientific and oncology consultants, they have developed a rational, composite formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Their lead product, PRP, is making headlines across the world as it moves successfully from preclinical development to its First-In-Human study.

Currently, the market cap for PPCHD is $3.99 million with a per-share price of $1.30. The success of the anticipated First-In-Human study could put this company on the road toward mid- to large-cap status. It would be a huge payoff for investors investing now, while market cap is low, as PPCHD marches onto their successful First-In-Human study.

Read more: http://m.digitaljournal.com/pr/3348922#ixzz4hSWSPa4a